BioRestorative Therapies vs Cardiff Oncology
Cardiff Oncology reported revenue of $1 million in fiscal 2025, 1.5 times BioRestorative Therapies' $0 million in fiscal 2025. BioRestorative Therapies' revenue fell 10.3% in its latest year, and Cardiff Oncology's fell 13.2%. BioRestorative Therapies had an operating margin of -4350.1%, against -8256.3% at Cardiff Oncology. Free cash flow was −$11 million at BioRestorative Therapies and −$38 million at Cardiff Oncology.
Side by side
| BioRestorative Therapies | Cardiff Oncology | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $1M |
| Revenue growth | −10.3% | −13.2% |
| Revenue growth a year, last 5 years | 32.0% | 8.4% |
| Gross margin | 93.4% | — |
| Operating margin | −4,350.1% | −8,256.3% |
| Net margin | −3,959.4% | −7,732.0% |
| Free cash flow | −$11M | −$38M |
| Free cash flow margin | −3,031.7% | −6,402.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 15.8% | 40.3% |
| Last close | $1.31 | $0.89 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $1.1 million, sold $0 |
| Piotroski F-score | — | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BioRestorative TherapiesCardiff Oncology
Operating margin
Percent of revenue
BioRestorative TherapiesCardiff Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioRestorative TherapiesCardiff Oncology
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BioRestorative Therapies and Cardiff Oncology pages.